Opinion|Videos|March 21, 2024
Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
Side effect profiles driven by fruquintinib use are discussed.
Advertisement
Episodes in this series
Advertisement
Related to this article
Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5